Endocrine Abstracts

Lenvatinib is a tyrosine kinase inhibitor (TKI), approved for the management of locally recurrent or metastatic, progressive, radioactive iodine–refractory differentiated thyroid cancer (DTC). A side effect of this drug is the tracheoesophageal fistula, described in 14.7% of patients. When this side effect is present, the interruption/withdrawn of the TKI is required and in this case no valid therapeutic options are described. We present the case of a 63-year-old woman pa...

Lipid metabolism diseases are continuously increasing due to lifestyle changes, and many studies have reported that the incidence of other cancers increases in these diseases. Thyroid cancer occurs frequently, and its prognosis is good; therefore, there are many survivors. In this study, we aimed to confirm whether thyroid cancer itself affects the risk of secondary cancer in patients with lipid metabolic disease and the factors affecting this risk through analysis of institut...

Background: The incidence of thyroid cancer (TC) has been increasing in recent years while mortality has remained stable. The cause of this increase is unclear, although several hypotheses have been proposed. While the increased incidence may only be apparent due to increased testing, there is data that suggest that there may be a real increase in incidence related to different risk factors. The aim of this meta-analysis was to determine the current incidence of TC in Europe.<...

Introduction: The association between thyroid cancer and thyrotoxicosis is rare and, in particular, autonomous hyperfunctioning metastasis of differentiated thyroid cancer (TC) are seldom described, with a prevalence of 0.71%. Althought most hyperfunctioning metastasis are derived from follicular thyroid cancer (FTC), metastasis from papillary thyroid cancer (PTC) have been also reported. Bone metastasis account for the majority of cases. Hyperfunctioning TC metastasis have be...

Objectives: To evaluate the quality of life (QoL) in patients with differentiated thyroid cancer (DTC) by a validated thyroid-specific questionnaire and to identify factors with significant impact on the QoL.Methods: Two hundred DTC patients, treated in one tertiary center, were recruited in the study. One year after the thyroid surgery, they completed the QoL Cancer Survivor Instrument – Thyroid version questionnaire. The questionnaire assessed the...

Objective: Thyroid cancer (TC) screening in acromegaly is a controversial topic. The Endocrine Society opposes routine TC screening in acromegaly patients without a palpable nodule, and the American Thyroid Association does not consider acromegaly to be a high-risk condition for developing TC. However, acromegaly is associated with an increased risk of TC, and some centers opt for thyroid ultrasound screening even in the absence of palpable thyroid nodules. Being one of the su...

Selpercatinib is a specific RET inhibitor, highly effective in the treatment of advanced RET-mutant medullary thyroid carcinoma (MTC). The consequences of selpercatinib administration in MTC patients who have not undergone thyroid surgery are still unknown. We report the case of an 84-year-old man undergoing investigations for worsening diarrhea and weight loss. Upon a neck ultrasound scan and blood exams that pointed out high levels of both calcitonin (CT, 20.583 ng/l) and ca...

Background: Recent guidelines recommend lobectomy (LOB) when compared to total thyroidectomy (TTX) as the preferred approach for patients with low-risk differentiated thyroid cancer (DTC). Major advantages are the avoidance of lifelong hormone replacement therapy and the absence of any risk for contralateral recurrent laryngeal nerve palsy and postoperative hypoparathyroidism with no or minimal increased risk for adverse oncological outcomes. However, this limited approached s...

Introduction: Vandetanib is a multikinase inhibitor of the family of EGF receptor inhibitors whose main indication is medullary thyroid cancer at the locally advanced or metastatic stage. It is associated with cutaneous toxicity represented mainly by acneiform eruptions and hand-foot syndrome appearing a few weeks after the start of treatment. Folliculate is rare We report a rare case of late chronic folliculate of the lower limbs secondary to vandetanib.<p class="abstext"...